Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Feb;61(3):433-443.
doi: 10.1111/apt.18451. Epub 2024 Dec 19.

Meta-Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction-Associated Steatotic Liver Disease

Soroor Owrangi  1 , James M Paik  1   2   3 , Pegah Golabi  1   2   3 , Leyla de Avila  1   2 , Ryuki Hashida  1 , Ariana Nader  1 , Annette Paik  1   2 , Linda Henry  1   2   3 , Zobair M Younossi  1   2   3
Affiliations
Meta-Analysis

Meta-Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction-Associated Steatotic Liver Disease

Soroor Owrangi et al. Aliment Pharmacol Ther. 2025 Feb.

Abstract

Background and aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is responsible for a significant global health burden. Despite this burden, the prevalence and mortality of MASLD-related cirrhosis remain inadequately defined, hindering effective public health strategies. This study aimed to estimate the global prevalence and mortality associated with MASLD-related cirrhosis.

Methods: A systematic search of PubMed, Ovid MEDLINE, EMBASE, Web of Science and SCOPUS was conducted using keywords related to MASLD and cirrhosis from inception of each database used through June 2024. COVIDENCE was used for abstract and manuscript review. MASLD populations were categorised into 'general practice setting' and 'high risk setting', which indicated studies from inpatient setting or those referred for liver biopsy for an indication (elevated liver enzymes). Our data extraction and quality assessment followed PRISMA guidelines. A random-effects model was utilised for meta-analysis.

Results: From 7924 identified articles, 35 studies comprising 513,742 patients with MASLD met the inclusion criteria. The pooled global prevalence of cirrhosis among MASLD patients was 3.26% (95% CI: 2.47%-4.31%) in general practice settings (4 studies) and 14.51% (95% CI: 11.22%-18.57%) among those in inpatient settings or referred for liver biopsy (31 studies). Regionally, higher prevalence rates in high-risk settings were observed in North America and Australia (18.38%; 95% CI: 9.06%-33.75%), followed by Europe (10.16%; 95% CI: 5.71%-17.44%) and Asia (9.12%; 95% CI: 6.11%-13.40%) (p = 0.007). Notably, ICD-based diagnoses indicated a significantly higher prevalence of cirrhosis (27.43%) compared to those diagnosed by liver biopsy (13.24%; p < 0.001). The pooled all-cause mortality rate for MASLD-cirrhosis patients was estimated at 7.91 per 100 person-years (95% CI: 4.44-13.71) (9 studies).

Conclusions: This meta-analysis underscores the substantial prevalence of cirrhosis among MASLD patients and highlights significant geographic and demographic variability, calling for improved screening and management strategies.

Keywords: MASH; MASLD; NAFLD; NASH; advanced fibrosis; cirrhosis; mortality.

PubMed Disclaimer

References

    1. M. E. Rinella, J. V. Lazarus, V. Ratziu, et al., “A Multi‐Society Delphi Consensus Statement on New Fatty Liver Disease Nomenclature,” Journal of Hepatology 79, no. 6 (2023): 1542–1556, https://doi.org/10.1016/j.jhep.2023.06.003.
    1. Z. M. Younossi, M. Stepanova, Y. Younossi, et al., “Epidemiology of Chronic Liver Diseases in the USA in the Past Three Decades,” Gut 69, no. 3 (2020): 564–568, https://doi.org/10.1136/gutjnl‐2019‐318813.
    1. Z. M. Younossi, P. Golabi, J. M. Paik, A. Henry, C. Van Dongen, and L. Henry, “The Global Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review,” Hepatology 77, no. 4 (2023): 1335–1347, https://doi.org/10.1097/HEP.0000000000000004.
    1. M. H. Le, Y. H. Yeo, B. Zou, et al., “Forecasted 2040 Global Prevalence of Nonalcoholic Fatty Liver Disease Using Hierarchical Bayesian Approach,” Clinical and Molecular Hepatology 28, no. 4 (2022): 841–850, https://doi.org/10.3350/cmh.2022.0239.
    1. C. Estes, H. Razavi, R. Loomba, Z. Younossi, and A. J. Sanyal, “Modeling the Epidemic of Nonalcoholic Fatty Liver Disease Demonstrates an Exponential Increase in Burden of Disease,” Hepatology 67, no. 1 (2018): 123–133, https://doi.org/10.1002/hep.29466.

LinkOut - more resources